bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models
Authors: Cook Sangar Michelle L. , Genovesi Laura A. , Nakamoto Madison W. , Davis Melissa J. , Knobluagh Sue E. , Ji Pengxiang , Millar Amanda , Wainwright Brandon J. , Olson James M.
Published: April 2023

Figure S1 shows the delineation of the tumor in MRI images.
Supplementary table s3 from Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers
Authors: Hata Tatsuo , Dal Molin Marco , Hong Seung-Mo , Tamura Koji , Suenaga Masaya , Yu Jun , Sedogawa Hiraku , Weiss Matthew J. , Wolfgang Christopher L. , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael G.
Published: April 2023

Supplementary Table S3. Univariate and multivariate analysis of pancreatic cyst fluid methylated DNA biomarkers.
Supplemental Table 2 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Authors: Thompson Jeffrey C. , Yee Stephanie S. , Troxel Andrea B. , Savitch Samantha L. , Fan Ryan , Balli David , Lieberman David B. , Morrissette Jennifer D. , Evans Tracey L. , Bauml Joshua , Aggarwal Charu , Kosteva John A. , Alley Evan , Ciunci Christine , Cohen Roger B. , Bagley Stephen , Stonehouse-Lee Susan , Sherry Victoria E. , Gilbert Elizabeth , Langer Corey , Vachani Anil , Carpenter Erica L.
Published: April 2023

Tissue next-generation sequencing gene coverage. A: Illumina TruSeq panel (47 genes), and B: Penn Precision Panel (20 genes)
Supplemental Table 1 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Authors: Thompson Jeffrey C. , Yee Stephanie S. , Troxel Andrea B. , Savitch Samantha L. , Fan Ryan , Balli David , Lieberman David B. , Morrissette Jennifer D. , Evans Tracey L. , Bauml Joshua , Aggarwal Charu , Kosteva John A. , Alley Evan , Ciunci Christine , Cohen Roger B. , Bagley Stephen , Stonehouse-Lee Susan , Sherry Victoria E. , Gilbert Elizabeth , Langer Corey , Vachani Anil , Carpenter Erica L.
Published: April 2023

Circulating tumor DNA next-generation sequencing gene coverage
Supplemental Figure 1 from Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Authors: Thompson Jeffrey C. , Yee Stephanie S. , Troxel Andrea B. , Savitch Samantha L. , Fan Ryan , Balli David , Lieberman David B. , Morrissette Jennifer D. , Evans Tracey L. , Bauml Joshua , Aggarwal Charu , Kosteva John A. , Alley Evan , Ciunci Christine , Cohen Roger B. , Bagley Stephen , Stonehouse-Lee Susan , Sherry Victoria E. , Gilbert Elizabeth , Langer Corey , Vachani Anil , Carpenter Erica L.
Published: April 2023

Total amount of cfDNA extracted from each patient sample
Supplementary figure legend from Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
Authors: Orillion Ashley , Hashimoto Ayumi , Damayanti Nur , Shen Li , Adelaiye-Ogala Remi , Arisa Sreevani , Chintala Sreenivasulu , Ordentlich Peter , Kao Chingai , Elzey Bennett , Gabrilovich Dmitry , Pili Roberto
Published: April 2023

Supplementary figure legend
Supplementary Material from Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Authors: Advani Ranjana H. , Lebovic Daniel , Chen Andy , Brunvand Mark , Goy Andre , Chang Julie E. , Hochberg Ephraim , Yalamanchili Sreeni , Kahn Robert , Lu Dan , Agarwal Priya , Dere Randall C. , Hsieh Hsin-Ju , Jones Surai , Chu Yu-Waye , Cheson Bruce D.
Published: April 2023

Supplementary Figure 1. Summary of study enrollment by dose level and disease cohort. All patients were evaluated for safety and anti-tumor activity. Supplementary Table 1. Enrollment. Supplementary Table 2. Treatment-emergent adverse events occurring in at least 10% of patients treated with pinatuzumab vedotin by pooled dose cohorts and histology. Supplementary Table 3. Incidence of treatment-emergent peripheral neuropathy (PN) among patients with prior PN and/or prior vinca alkaloid treatment. Supplementary Figure 2. Cycle 1 and 3 mean ({plus minus} SD) serum/plasma concentration-time curves for total antibody, conjugate (evaluated as acMMAE), and MMAE following 2.4-mg/kg dose per cycle for every three-week cycle of single-agent pinatuzumab vedotin in B-cell lymphoma patients. Supplementary Table 4. Mean (SD) values for selected serum/plasma PK parameters of total antibody, conjugate (evaluated as acMMAE) and unconjugated MMAE following Cycle 1 doses of pinatuzumab vedotin in PK-evaluable CLL patients. Supplementary Table 5. Tabulation of demographic/clinical features for r/r NHL (combined DLBCL and iNHL) patients with and without PFS events.
Supplemental Figure 6 from PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Authors: Lok Benjamin H. , Gardner Eric E. , Schneeberger Valentina E. , Ni Andy , Desmeules Patrice , Rekhtman Natasha , de Stanchina Elisa , Teicher Beverly A. , Riaz Nadeem , Powell Simon N. , Poirier John T. , Rudin Charles M.
Published: April 2023

Animal weights on drug efficacy studies.
Supplementary Table 3 from Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Yuan Jianda , Postow Michael A. , Wong Phillip , Capone Mariaelena , Madonna Gabriele , Khammari Amir , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Martus Peter , Dreno Brigitte , Ascierto Paolo A. , Wolchok Jedd D. , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Changes associated with overall survival and their correlation with clinical responses in sub-cohorts. Analyses were limited to patients with available data at all three time points or limited to patients treated with ipilimumab monotherapy at 3 mg/kg bodyweight. *Early defines a second time-point, ranging from 2-8 weeks after start (BL) of ipilimumab. #Delayed defines a third time-point, ranging from 8-14 weeks after start (BL) of ipilimumab.
Figure S3 from Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Authors: Pham Lan V. , Huang Shengjian , Zhang Hui , Zhang Jun , Bell Taylor , Zhou Shouhao , Pogue Elizabeth , Ding Zhiyong , Lam Laura , Westin Jason , Davis R. Eric , Young Ken H. , Medeiros L. Jeffrey , Ford Richard J. , Nomie Krystle , Zhang Leo , Wang Michael
Published: April 2023

Representative venetoclax-resistant (BJAB and HT) cell lines were treated with venetoclax at a 1:1 ratio drug combinations with PI3K inhibitors (idelalisib and KA2237) or an AKT inhibitor (MK-2206) in a concentration-dependent manner for 72 h, and cell viability was assessed. The highest starting concentration for each drug was 20 mM. The following are the drug combinations: 100 nM: 20 mM; 50 nM:10 mM; 25 nM:5 mM; 12.5 nM:2.5 mM; 6.25 nM:1.25 mM; 3.1 nM:0.61 mM; 1.5 nM:0.3 mM. Data from two independent experiments performed in triplicate are shown. (B) MAPK-pT202-Y204, MEK1-pS217-S221, and JNK-pT183-Y185 protein levels were plotted against the corresponding venetoclax IC50 for each cell line. Spearman's rank correlation coefficient, and p values determined of the above analysis. P values less than 0.05 indicate significant correlations.
Figure S2 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
Authors: Kyi Chrisann , Roudko Vladimir , Sabado Rachel , Saenger Yvonne , Loging William , Mandeli John , Thin Tin Htwe , Lehrer Deborah , Donovan Michael , Posner Marshall , Misiukiewicz Krzysztof , Greenbaum Benjamin , Salazar Andres , Friedlander Philip , Bhardwaj Nina
Published: April 2023

Supplemental Figure 2. Hierarchical clustering of total gene expression of PBMC and tumor RNA samples. Only genes commonly expressed in PBMC and tumor samples are shown. Of note, up-regulation of specific genes at tumor site may come from tumor rather immune cells. On x-axis, each column represents patient at specific treatment time point, as numbered below. For example, 002- C1W1 is patient 002 at time point Cycle 1 week1. 1 - 002_Screen 12 - 004_Screen 2 - 002_C1W1 13 - 004_C1W2 3 - 002_C1W3 14 - 008_Screen 4 - 002_C1W7 15 - 008_C1W1 5 - 002_C1W10 16 - 008_C1W3 6 - 002_C2W11 17 - 008_C1W7 7 - 002_C2W12 18 - 008_C1W10 8 - 002_C2W13 9 - 002_C2W17 10 - 002_C2W20 11 - 002_C2W26
Figure S1 from Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
Authors: Kyi Chrisann , Roudko Vladimir , Sabado Rachel , Saenger Yvonne , Loging William , Mandeli John , Thin Tin Htwe , Lehrer Deborah , Donovan Michael , Posner Marshall , Misiukiewicz Krzysztof , Greenbaum Benjamin , Salazar Andres , Friedlander Philip , Bhardwaj Nina
Published: April 2023

Supplemental Figure 1. Enrichments of Broad collection of immunological gene signatures in PBMC of SD (patient 002) and PD patients (patients 004 and 008). (A) non-supervised hierarchical clustering of selected gene signatures (FDR < 0,25). Gene names of enriched genesets are publicly available online at MSigDB: http://software.broadinstitute.org/gsea/msigdb/index.jsp. (B) Comparison of genesets enrichment scores between SD and PD patients. Positive values indicate enrichment in SD patient, while negative values - enrichment in PD patients. Enrichments were calculated based on outputs of GSEA analysis. X-axis: [Signal(SD) - Signal(PD)] / Signal(SD), where Signal is enrichment signal strength of geneset in patient 002 with SD response. Y-axis: [NES(SD) - NES(PD)] / NES(SD), where NES(SD) is normalized enrichment score of geneset in patient 002.
Supplementary Legends, Table from Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI
Authors: Erstad Derek J. , Sojoodi Mozhdeh , Taylor Martin S. , Jordan Veronica Clavijo , Farrar Christian T. , Axtell Andrea L. , Rotile Nicholas J. , Jones Chloe , Graham-O'Regan Katherine A. , Ferreira Diego S. , Michelakos Theodoros , Kontos Filippos , Chawla Akhil , Li Shen , Ghoshal Sarani , Chen Yin-Ching Iris , Arora Gunisha , Humblet Valerie , Deshpande Vikram , Qadan Motaz , Bardeesy Nabeel , Ferrone Cristina R. , Lanuti Michael , Tanabe Kenneth K. , Caravan Peter , Fuchs Bryan C.
Published: April 2023

Supplementary Legends, Table
Supplementary Materials from B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Authors: Zhang Leo , Nomie Krystle , Zhang Hui , Bell Taylor , Pham Lan , Kadri Sabah , Segal Jeremy , Li Shaoying , Zhou Shouhao , Santos David , Richard Shawana , Sharma Shruti , Chen Wendy , Oriabure Onyekachukwu , Liu Yang , Huang Shengjian , Guo Hui , Chen Zhihong , Tao Wenjing , Li Carrie , Wang Jack , Fang Bingliang , Wang Jacqueline , Li Lei , Badillo Maria , Ahmed Makhdum , Thirumurthi Selvi , Huang Steven Y. , Shao Yiping , Lam Laura , Yi Qing , Wang Y. Lynn , Wang Michael
Published: April 2023

Include supplementary Figure S1-S4 legends; Supplementary Table S1 and S4; and list Supplementary Table S2 and S3 titles. Supplementary Table S1. The panel of drugs used in vitro and in vivo with their doses and duration. Supplementary Table S4. The mean passage time per generation for 5 generations
Supplemental Tables 2-6 from Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase
Authors: Kalinina Juliya , Ahn Jun , Devi Narra S. , Wang Liya , Li Yuancheng , Olson Jeffrey J. , Glantz Michael , Smith Thomas , Kim Ella L. , Giese Alf , Jensen Randy L. , Chen Clark C. , Carter Bob S. , Mao Hui , He Miao , Van Meir Erwin G.
Published: April 2023

Suppl. Table 2. CSF and Matching Tissues Available for the Study Suppl. Table 3. Metabolite concentrations in the three cohorts (t-test Statistics) Suppl. Table 4. Site-specific thresholds for D-/L-2HG Suppl. Table 5. Information about site-specific accuracy for D-2HG Suppl. Table 6. Tumor tissue sample demographics tested in parallel by MS and NMR
Suppl. Table 1 from Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase
Authors: Kalinina Juliya , Ahn Jun , Devi Narra S. , Wang Liya , Li Yuancheng , Olson Jeffrey J. , Glantz Michael , Smith Thomas , Kim Ella L. , Giese Alf , Jensen Randy L. , Chen Clark C. , Carter Bob S. , Mao Hui , He Miao , Van Meir Erwin G.
Published: April 2023

Suppl. Table 1. Histology, age, gender, diagnosis, site of CSF draws, longitudinal # and IDH1/2 mutation status of 84 tumor samples analyzed. Highlighted in 'yellow' are CSF samples that tested positive for IDH1 mutant staining, while their DNA indicated WT IDH.
Supplementary Figure legends from Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Authors: Schøler Lone V. , Reinert Thomas , Ørntoft Mai-Britt W. , Kassentoft Christine G. , Árnadóttir Sigrid S. , Vang Søren , Nordentoft Iver , Knudsen Michael , Lamy Philippe , Andreasen Ditte , Mortensen Frank V. , Knudsen Anders R. , Stribolt Katrine , Sivesgaard Kim , Mouritzen Peter , Nielsen Hans J. , Laurberg Søren , Ørntoft Torben F. , Andersen Claus L.
Published: April 2023

Supplementary Figure legends
Figure S4 from Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer
Authors: Schøler Lone V. , Reinert Thomas , Ørntoft Mai-Britt W. , Kassentoft Christine G. , Árnadóttir Sigrid S. , Vang Søren , Nordentoft Iver , Knudsen Michael , Lamy Philippe , Andreasen Ditte , Mortensen Frank V. , Knudsen Anders R. , Stribolt Katrine , Sivesgaard Kim , Mouritzen Peter , Nielsen Hans J. , Laurberg Søren , Ørntoft Torben F. , Andersen Claus L.
Published: April 2023

Comparison of serial ctDNA analysis performed using SSV and SPM ddPCR assays.
Supplementary Table 2 from An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
Authors: Girard Luc , Rodriguez-Canales Jaime , Behrens Carmen , Thompson Debrah M. , Botros Ihab W. , Tang Hao , Xie Yang , Rekhtman Natasha , Travis William D. , Wistuba Ignacio I. , Minna John D. , Gazdar Adi F.
Published: April 2023

Validation of the Classifier in 23 public lung cancer expression datasets
Supplemental Data from Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer
Authors: Parsons Heather A. , Beaver Julia A. , Cimino-Mathews Ashley , Ali Siraj M. , Axilbund Jennifer , Chu David , Connolly Roisin M. , Cochran Rory L. , Croessmann Sarah , Clark Travis A. , Gocke Christopher D. , Jeter Stacie C. , Kennedy Mark R. , Lauring Josh , Lee Justin , Lipson Doron , Miller Vincent A. , Otto Geoff A. , Rosner Gary L. , Ross Jeffrey S. , Slater Shannon , Stephens Philip J. , VanDenBerg Dustin A. , Wolff Antonio C. , Young Lauren E. , Zabransky Daniel J. , Zhang Zhe , Zorzi Jane , Stearns Vered , Park Ben H.
Published: April 2023

Figure S1. Oncoprint of Somatic Genomic Alterations in Metastatic Biopsies of 20 Triple Negative Breast Cancers. Table S1. Characteristics of genomic alterations from metastatic tumor biopsies
Supplementary Material from An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
Authors: Girard Luc , Rodriguez-Canales Jaime , Behrens Carmen , Thompson Debrah M. , Botros Ihab W. , Tang Hao , Xie Yang , Rekhtman Natasha , Travis William D. , Wistuba Ignacio I. , Minna John D. , Gazdar Adi F.
Published: April 2023

Extended HTG EdgeSeq methodology
Supplementary Figures from An Expression Signature as an Aid to the Histologic Classification of Non–Small Cell Lung Cancer
Authors: Girard Luc , Rodriguez-Canales Jaime , Behrens Carmen , Thompson Debrah M. , Botros Ihab W. , Tang Hao , Xie Yang , Rekhtman Natasha , Travis William D. , Wistuba Ignacio I. , Minna John D. , Gazdar Adi F.
Published: April 2023

Sup. fig. 1, signature optimization; sup. fig. 2, Score plot of both signatures; sup. fig. 3, score box plots; sup. fig. 4, association between score and tumor differentiation; sup. fig. 5, association of score with survival; sup. fig. 6, HTG EdgeSeq assay on 25 samples
Supplementary Figure S1 from Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER+/HER2− Breast Cancer
Authors: van der Velden Bas H.M. , Elias Sjoerd G. , Bismeijer Tycho , Loo Claudette E. , Viergever Max A. , Wessels Lodewyk F.A. , Gilhuijs Kenneth G.A.
Published: April 2023

Hazard raô€†Ÿo of intermediate contralateral parenchymal enhancement (CPE) (yellow) and high CPE (green) with respect to low CPE. CPE was calculated as the average of the late enhancement values above the threshold. CPE groups were subsequently obtained by spliô€†«ng CPE on terô€†Ÿles. The colored bands indicate 95% confidence intervals. The doô€†©ed line at 90% represents the original threshold.
Figure S7 from Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3–MYC Interactions as a Target in Pancreatic Cancer
Authors: Beglyarova Natalya , Banina Eugenia , Zhou Yan , Mukhamadeeva Ramilia , Andrianov Grigorii , Bobrov Egor , Lysenko Elena , Skobeleva Natalya , Gabitova Linara , Restifo Diana , Pressman Max , Serebriiskii Ilya G. , Hoffman John P. , Paz Keren , Behrens Diana , Khazak Vladimir , Jablonski Sandra A. , Golemis Erica A. , Weiner Louis M. , Astsaturov Igor
Published: April 2023

ERCC3 interacting proteins.
Figure S3 from Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Authors: Delord Jean-Pierre , Robert Caroline , Nyakas Marta , McArthur Grant A. , Kudchakar Ragini , Mahipal Amit , Yamada Yasuhide , Sullivan Ryan , Arance Ana , Kefford Richard F. , Carlino Matteo S. , Hidalgo Manuel , Gomez-Roca Carlos , Michel Daniela , Seroutou Abdelkader , Aslanis Vassilios , Caponigro Giordano , Stuart Darrin D. , Moutouh-de Parseval Laure , Demuth Tim , Dummer Reinhard
Published: April 2023

Best percentage change in sum of longest diameters in target lesion from baseline, by patient, treatment group, and mutation status, in patients with BRAFi-naive (A) and pretreated (B) melanoma. Grouped analysis of patients in the dose-escalation and -expansion phases.
Figure S2 from Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Authors: Delord Jean-Pierre , Robert Caroline , Nyakas Marta , McArthur Grant A. , Kudchakar Ragini , Mahipal Amit , Yamada Yasuhide , Sullivan Ryan , Arance Ana , Kefford Richard F. , Carlino Matteo S. , Hidalgo Manuel , Gomez-Roca Carlos , Michel Daniela , Seroutou Abdelkader , Aslanis Vassilios , Caponigro Giordano , Stuart Darrin D. , Moutouh-de Parseval Laure , Demuth Tim , Dummer Reinhard
Published: April 2023

(A) Average body weight of mice treated with each BRAF inhibitor in the experiment depicted in Figure 1C; (B) Encorafenib plasma exposure in mice following the last dose from the experiment depicted in Figure 1C. To estimate daily exposure on the BID regimen, multiply the AUC x 2. Encorafenib is 98.6% protein bound in mouse plasma; (C) Gastric hyperplasia and hyperkeratosis observed in the forestomach of mice treated with BRAFi. Hematoxylin and eosin stains of forestomach sections from mice following 14 days of treatment with vehicle, encorafenib, dabrafenib, or vemurafenib from the study depicted in Figure 1C.
Supplementary table S4 from Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis
Authors: Paauwe Madelon , Schoonderwoerd Mark J.A. , Helderman Roxan F.C.P. , Harryvan Tom J. , Groenewoud Arwin , van Pelt Gabi W. , Bor Rosalie , Hemmer Danielle M. , Versteeg Henri H. , Snaar-Jagalska B. Ewa , Theuer Charles P. , Hardwick James C.H. , Sier Cornelis F.M. , ten Dijke Peter , Hawinkels Lukas J.A.C.
Published: April 2023

Characterization of patient-derived NFs and CAFs
Supplementary Table 2 from Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression
Authors: Borcherding Nicholas , Voigt Andrew P. , Liu Vincent , Link Brian K. , Zhang Weizhou , Jabbari Ali
Published: April 2023

Supplementary Table 2
Supplementary table S1 from Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis
Authors: Paauwe Madelon , Schoonderwoerd Mark J.A. , Helderman Roxan F.C.P. , Harryvan Tom J. , Groenewoud Arwin , van Pelt Gabi W. , Bor Rosalie , Hemmer Danielle M. , Versteeg Henri H. , Snaar-Jagalska B. Ewa , Theuer Charles P. , Hardwick James C.H. , Sier Cornelis F.M. , ten Dijke Peter , Hawinkels Lukas J.A.C.
Published: April 2023

Patient characteristics of cohort used for endoglin expression and survival analysis
Figure S1 from Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression
Authors: Borcherding Nicholas , Voigt Andrew P. , Liu Vincent , Link Brian K. , Zhang Weizhou , Jabbari Ali
Published: April 2023

Figure S1
Supplementary figure S5 from Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis
Authors: Paauwe Madelon , Schoonderwoerd Mark J.A. , Helderman Roxan F.C.P. , Harryvan Tom J. , Groenewoud Arwin , van Pelt Gabi W. , Bor Rosalie , Hemmer Danielle M. , Versteeg Henri H. , Snaar-Jagalska B. Ewa , Theuer Charles P. , Hardwick James C.H. , Sier Cornelis F.M. , ten Dijke Peter , Hawinkels Lukas J.A.C.
Published: April 2023

Tumor formation and angiogenesis after co-injection with WT/ENG KO MEFs
Supplementary Tables S7 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape
Authors: Wang Zixing , Kim Tae Beom , Peng Bo , Karam Jose , Creighton Chad , Joon Aron , Kawakami Fumi , Trevisan Patricia , Jonasch Eric , Chow Chi-Wan , Canales Jaime Rodriguez , Tamboli Pheroze , Tannir Nizar , Wood Christopher , Monzon Federico , Baggerly Keith , Varella-Garcia Marileila , Czerniak Bogdan , Wistuba Ignacio , Mills Gordon , Shaw Kenna , Chen Ken , Sircar Kanishka
Published: April 2023

Table S7a. Ingenuity Pathway Analysis of SRCC vs RCC Table S7b. Ingenuity Pathway Analysis of SccRCC vs advanced stage ccRCC Table S7c. Ingenuity Pathway Analysis of E vs S components of ccRCC
Supplementary Figures S1, S2 from Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Authors: Spino Marissa , Kurz Sylvia C. , Chiriboga Luis , Serrano Jonathan , Zeck Briana , Sen Namita , Patel Seema , Shen Guomiao , Vasudevaraja Varshini , Tsirigos Aristotelis , Suryadevara Carter M. , Frenster Joshua D. , Tateishi Kensuke , Wakimoto Hiroaki , Jain Rajan , Riina Howard A. , Nicolaides Theodore P. , Sulman Erik P. , Cahill Daniel P. , Golfinos John G. , Isse Kumiko , Saunders Laura R. , Zagzag David , Placantonakis Dimitris G. , Snuderl Matija , Chi Andrew S.
Published: April 2023

Supplementary Figures S1 and S2, new figures
Supplementary Figure S1 from Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors
Authors: Singhi Aatur D. , Liu Ta-Chiang , Roncaioli Justin L. , Cao Dengfeng , Zeh Herbert J. , Zureikat Amer H. , Tsung Allan , Marsh J. Wallis , Lee Kenneth K. , Hogg Melissa E. , Bahary Nathan , Brand Randall E. , McGrath Kevin M. , Slivka Adam , Cressman Kristi L. , Fuhrer Kimberly , O'Sullivan Roderick J.
Published: April 2023

Comparative analysis of DAXX/ATRX protein expression and ALT in paired primary and metastatic PanNETs. Patient with a PanNET (A) that is characterized by loss of ATRX expression (C) and ALT (E) by telomere-specific FISH. Within 2 years, the patient developed a distant metastasis within a non-regional lymph node (B) that also demonstrates ATRX loss (D) and is ALT-positive (F).
Supplemental Table 2 from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Parseghian Christine M. , Parikh Nila U. , Wu Ji Yuan , Jiang Zhi-Qin , Henderson Laura , Tian Feng , Pastor Brice , Ychou Marc , Raghav Kanwal , Dasari Arvind , Fogelman David R. , Katsiampoura Anastasia D. , Menter David G. , Wolff Robert A. , Eng Cathy , Overman Michael J. , Thierry Alain R. , Gallick Gary E. , Kopetz Scott
Published: April 2023

Symptom-specific dose adjustment tables.
Supplemental Table 1 from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Authors: Parseghian Christine M. , Parikh Nila U. , Wu Ji Yuan , Jiang Zhi-Qin , Henderson Laura , Tian Feng , Pastor Brice , Ychou Marc , Raghav Kanwal , Dasari Arvind , Fogelman David R. , Katsiampoura Anastasia D. , Menter David G. , Wolff Robert A. , Eng Cathy , Overman Michael J. , Thierry Alain R. , Gallick Gary E. , Kopetz Scott
Published: April 2023

Operating characteristics. A summary of the probability of stopping the trial early for the indicated true response rates.
Supplementary Materials and Methods from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
Authors: Kang Ya'an , Roife David , Lee Yeonju , Lv Hailong , Suzuki Rei , Ling Jianhua , Rios Perez Mayrim V. , Li Xinqun , Dai BingBing , Pratt Michael , Truty Mark J. , Chatterjee Deyali , Wang Huamin , Thomas Ryan M. , Wang Yu , Koay Eugene J. , Chiao Paul J. , Katz Matthew H. , Fleming Jason B.
Published: April 2023

HPaSteC and Media: Western blot and ELISA assay: Vectra Automated Quantitative Pathology Imaging System (VAQPIS, PerkinElmer): Double Immunofluorescence staining (IF), and Vectra multispectral analysis: Supplementary figure legends:
Table S1 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
Authors: Shattuck-Brandt Rebecca L. , Chen Sheau-Chiann , Murray Emily , Johnson Christopher Andrew , Crandall Holly , O'Neal Jamye F. , Al-Rohil Rami Nayef , Nebhan Caroline A. , Bharti Vijaya , Dahlman Kimberly B. , Ayers Gregory D. , Yan Chi , Kelley Mark C. , Kauffmann Rondi M. , Hooks Mary , Grau Ana , Johnson Douglas B. , Vilgelm Anna E. , Richmond Ann
Published: April 2023

Supplementary Table S1. A. NGS Summary.
Table S2 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Authors: Tuxen Ida Viller , Rohrberg Kristoffer Staal , Oestrup Olga , Ahlborn Lise Barlebo , Schmidt Ane Yde , Spanggaard Iben , Hasselby Jane P. , Santoni-Rugiu Eric , Yde Christina Westmose , Mau-Sørensen Morten , Nielsen Finn Cilius , Lassen Ulrik
Published: April 2023

Patient data
Supplementary Figure S5 from Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition
Authors: Shattuck-Brandt Rebecca L. , Chen Sheau-Chiann , Murray Emily , Johnson Christopher Andrew , Crandall Holly , O'Neal Jamye F. , Al-Rohil Rami Nayef , Nebhan Caroline A. , Bharti Vijaya , Dahlman Kimberly B. , Ayers Gregory D. , Yan Chi , Kelley Mark C. , Kauffmann Rondi M. , Hooks Mary , Grau Ana , Johnson Douglas B. , Vilgelm Anna E. , Richmond Ann
Published: April 2023

Supplementary Figure S5: Association Between Mutation Status and t Ratio.
Figure S1 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
Authors: Tuxen Ida Viller , Rohrberg Kristoffer Staal , Oestrup Olga , Ahlborn Lise Barlebo , Schmidt Ane Yde , Spanggaard Iben , Hasselby Jane P. , Santoni-Rugiu Eric , Yde Christina Westmose , Mau-Sørensen Morten , Nielsen Finn Cilius , Lassen Ulrik
Published: April 2023

Scatterplot PFS1 against PFS2
Supplementary legend from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Authors: Jovanović Bojana , Mayer Ingrid A. , Mayer Erica L. , Abramson Vandana G. , Bardia Aditya , Sanders Melinda E. , Kuba M. Gabriela , Estrada Monica V. , Beeler J. Scott , Shaver Timothy M. , Johnson Kimberly C. , Sanchez Violeta , Rosenbluth Jennifer M. , Dillon Patrick M. , Forero-Torres Andres , Chang Jenny C. , Meszoely Ingrid M. , Grau Ana M. , Lehmann Brian D. , Shyr Yu , Sheng Quanhu , Chen Sheau-Chiann , Arteaga Carlos L. , Pietenpol Jennifer A.
Published: April 2023

Supplementary legend
Supplemental Table 1 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Authors: Jovanović Bojana , Mayer Ingrid A. , Mayer Erica L. , Abramson Vandana G. , Bardia Aditya , Sanders Melinda E. , Kuba M. Gabriela , Estrada Monica V. , Beeler J. Scott , Shaver Timothy M. , Johnson Kimberly C. , Sanchez Violeta , Rosenbluth Jennifer M. , Dillon Patrick M. , Forero-Torres Andres , Chang Jenny C. , Meszoely Ingrid M. , Grau Ana M. , Lehmann Brian D. , Shyr Yu , Sheng Quanhu , Chen Sheau-Chiann , Arteaga Carlos L. , Pietenpol Jennifer A.
Published: April 2023

Breast Cancer Gene Panel (GeneWiz)
Supplemental Figure 3 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Authors: Jovanović Bojana , Mayer Ingrid A. , Mayer Erica L. , Abramson Vandana G. , Bardia Aditya , Sanders Melinda E. , Kuba M. Gabriela , Estrada Monica V. , Beeler J. Scott , Shaver Timothy M. , Johnson Kimberly C. , Sanchez Violeta , Rosenbluth Jennifer M. , Dillon Patrick M. , Forero-Torres Andres , Chang Jenny C. , Meszoely Ingrid M. , Grau Ana M. , Lehmann Brian D. , Shyr Yu , Sheng Quanhu , Chen Sheau-Chiann , Arteaga Carlos L. , Pietenpol Jennifer A.
Published: April 2023

Presence of Intratumoral and Stromal Tumor-Infiltrating Lymphocytes (TILs) did not Correlate with Pathological Responses
Supplementary Tables from CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma
Authors: Stracquadanio Giovanni , Vrugt Bart , Flury Renata , Schraml Peter , Würl Peter , Müller Thomas H. , Knippschild Uwe , Henne-Bruns Doris , Breitenstein Stefan , Clavien Pierre-Alain , Graf Rolf , Bond Gareth L. , Grochola Lukasz F.
Published: April 2023

Supplementary Tables
Supplemental Data Legends from CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma
Authors: Stracquadanio Giovanni , Vrugt Bart , Flury Renata , Schraml Peter , Würl Peter , Müller Thomas H. , Knippschild Uwe , Henne-Bruns Doris , Breitenstein Stefan , Clavien Pierre-Alain , Graf Rolf , Bond Gareth L. , Grochola Lukasz F.
Published: April 2023

Supplemental data legends
Table S1 to S5 from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Authors: Vandekerkhove Gillian , Todenhöfer Tilman , Annala Matti , Struss Werner J. , Wong Amanda , Beja Kevin , Ritch Elie , Brahmbhatt Sonal , Volik Stanislav V. , Hennenlotter Jörg , Nykter Matti , Chi Kim N. , North Scott , Stenzl Arnulf , Collins Colin C. , Eigl Bernhard J. , Black Peter C. , Wyatt Alexander W.
Published: April 2023

Excel file with all five supplemental tables, each contained on a separate tab. Table S1 describes the patient cohort and clinical characteristics. Table S2 describes the targets of our custom sequencing approach. Table S3 relates cfDNA yields and subsequent ctDNA fractions from all samples. Table S4 describes the somatic mutations identified. Table S5 describes the chromosomal rearrangements identified.
Supplementary Figures from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Authors: Vandekerkhove Gillian , Todenhöfer Tilman , Annala Matti , Struss Werner J. , Wong Amanda , Beja Kevin , Ritch Elie , Brahmbhatt Sonal , Volik Stanislav V. , Hennenlotter Jörg , Nykter Matti , Chi Kim N. , North Scott , Stenzl Arnulf , Collins Colin C. , Eigl Bernhard J. , Black Peter C. , Wyatt Alexander W.
Published: April 2023

File containing all 13 supplementary figures, complete with figure legends.
Supplementary Figure S2 from Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Authors: de Jonge Marthe M. , Auguste Aurélie , van Wijk Lise M. , Schouten Philip C. , Meijers Matty , ter Haar Natalja T. , Smit Vincent T.H.B.M. , Nout Remi A. , Glaire Mark A. , Church David N. , Vrieling Harry , Job Bastien , Boursin Yannick , de Kroon Cor D. , Rouleau Etienne , Leary Alexandra , Vreeswijk Maaike P.G. , Bosse Tjalling
Published: April 2023

Figure S2 shows that their is an unbiased natural devision between samples analyes by the oncoscan platform and the CGH Agilent platform.
Supplementary Data (Table S1, Figure S1, Figure S2, Figure S3) from Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
Authors: Coffey Greg P. , Feng Jiajia , Betz Andreas , Pandey Anjali , Birrell Matt , Leeds Janet M. , Der Kenneth , Kadri Sabah , Lu Pin , Segal Jeremy , Wang Y. Lynn , Michelson Glenn , Curnutte John T. , Conley Pamela B.
Published: April 2023

Supplemental Appendix (Table S1, Figure S1, Figure S2, Figure S3)
Supplementary Figure 1 from Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
Authors: Roife David , Dai Bingbing , Kang Ya'an , Rios Perez Mayrim V. , Pratt Michael , Li Xinqun , Fleming Jason B.
Published: April 2023

Tissue slices after treatment with Gemcitabine (100 µM) or Irinotecan (30 µM) for 48 hours were fixed and embedded for immunohistochemical staining of cleaved-Caspase 3 (40X magnification, Bars = 20 µm).
Supplementary Table 4. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Authors: Federico Sara M. , McCarville M. Beth , Shulkin Barry L. , Sondel Paul M. , Hank Jacquelyn A. , Hutson Paul , Meagher Michael , Shafer Aaron , Ng Catherine Y. , Leung Wing , Janssen William E. , Wu Jianrong , Mao Shenghua , Brennan Rachel C. , Santana Victor M. , Pappo Alberto S. , Furman Wayne L.
Published: April 2023

ADCC EC50 values of hu14.18K322A and dinutuximab.
Supplementary Table 2. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Authors: Federico Sara M. , McCarville M. Beth , Shulkin Barry L. , Sondel Paul M. , Hank Jacquelyn A. , Hutson Paul , Meagher Michael , Shafer Aaron , Ng Catherine Y. , Leung Wing , Janssen William E. , Wu Jianrong , Mao Shenghua , Brennan Rachel C. , Santana Victor M. , Pappo Alberto S. , Furman Wayne L.
Published: April 2023

Human anti-human antibody (HAHA) level and peak hu14.18K322A serum level by course and prior antibody therapy.
Supplementary Information from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

Supplementary Material and Figures "clean"
Supplementary Table 1. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Authors: Federico Sara M. , McCarville M. Beth , Shulkin Barry L. , Sondel Paul M. , Hank Jacquelyn A. , Hutson Paul , Meagher Michael , Shafer Aaron , Ng Catherine Y. , Leung Wing , Janssen William E. , Wu Jianrong , Mao Shenghua , Brennan Rachel C. , Santana Victor M. , Pappo Alberto S. , Furman Wayne L.
Published: April 2023

Individual pharmacokinetic parameters in 3 subpopulations (no prior 14.18 mAb, prior dinutuximab mAb, prior hu14.18K322A mAb).
Supplementary Figure 3. from A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Authors: Federico Sara M. , McCarville M. Beth , Shulkin Barry L. , Sondel Paul M. , Hank Jacquelyn A. , Hutson Paul , Meagher Michael , Shafer Aaron , Ng Catherine Y. , Leung Wing , Janssen William E. , Wu Jianrong , Mao Shenghua , Brennan Rachel C. , Santana Victor M. , Pappo Alberto S. , Furman Wayne L.
Published: April 2023

The left panel plots the calculated area under the concentration vs time curve (AUC) of hu14.18K322A and the right panel plots the highest observed serum concentration of hu14.18K322A (Cmax) against the pre-treatment concentration of HAHA antibodies, reported in units of optical density. There is no clear association between the concentration of HAHA at the start of treatment and the AUC of hu14.18K322A and the peak concentration of hu14.18K322A using the Spearman test.
Supplementary Figure 7 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

Effect of combined RG7388 and temsirolimus on colony-forming unit generation of CD34+ Hematopoietic Stem-Progenitor Cells
Supplementary Figure 4 from p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Authors: Moreno-Smith Myrthala , Lakoma Anna , Chen Zaowen , Tao Ling , Scorsone Kathleen A. , Schild Linda , Aviles-Padilla Kevin , Nikzad Rana , Zhang Yankai , Chakraborty Rikhia , Molenaar Jan J. , Vasudevan Sanjeev A. , Sheehan Vivien , Kim Eugene S. , Paust Silke , Shohet Jason M. , Barbieri Eveline
Published: April 2023

Bioluminescence data of xenograft tumors upon treatment suspension
Supplementary Figure Legends from IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
Authors: McMichael Elizabeth L. , Jaime-Ramirez Alena Cristina , Guenterberg Kristan D. , Luedke Eric , Atwal Lakhvir S. , Campbell Amanda R. , Hu Zhiwei , Tatum Armika S. , Kondadasula Sri Vidya , Mo Xiaokui , Tridandapani Susheela , Bloomston Mark , Ellison E. Christopher , Williams Terence M. , Bekaii-Saab Tanios , Carson William E.
Published: April 2023

Figure Legends for Supplementary data
Table S3 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Authors: Bhatia Shailender , Miller Natalie J. , Lu Hailing , Longino Natalie V. , Ibrani Dafina , Shinohara Michi M. , Byrd David R. , Parvathaneni Upendra , Kulikauskas Rima , ter Meulen Jan , Hsu Frank J. , Koelle David M. , Nghiem Paul
Published: April 2023

Table S3 lists immune-related genes with the most statistically significant differences in induction between clinical responders versus non-responders
Supplementary figure legends from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Ikeda Yuji , Park Jae-Hyun , Miyamoto Takashi , Takamatsu Naofumi , Kato Taigo , Iwasa Akiko , Okabe Shuhei , Imai Yuichi , Fujiwara Keiichi , Nakamura Yusuke , Hasegawa Kosei
Published: April 2023

Supplementary figure legends
Supplementary figure 6 from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Ikeda Yuji , Park Jae-Hyun , Miyamoto Takashi , Takamatsu Naofumi , Kato Taigo , Iwasa Akiko , Okabe Shuhei , Imai Yuichi , Fujiwara Keiichi , Nakamura Yusuke , Hasegawa Kosei
Published: April 2023

Growth inhibitory effects and cytotoxicity of OTS964 on ovarian cancer cells freshly isolated from patients.
Figure S3 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Authors: Bhatia Shailender , Miller Natalie J. , Lu Hailing , Longino Natalie V. , Ibrani Dafina , Shinohara Michi M. , Byrd David R. , Parvathaneni Upendra , Kulikauskas Rima , ter Meulen Jan , Hsu Frank J. , Koelle David M. , Nghiem Paul
Published: April 2023

Figure S3 shows quantification of new and induced TCR clones in tumor and blood
Figure S2 from Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma
Authors: Bhatia Shailender , Miller Natalie J. , Lu Hailing , Longino Natalie V. , Ibrani Dafina , Shinohara Michi M. , Byrd David R. , Parvathaneni Upendra , Kulikauskas Rima , ter Meulen Jan , Hsu Frank J. , Koelle David M. , Nghiem Paul
Published: April 2023

Figure S2 shows the expression of TLR4 receptor complex genes at baseline
Supplementary figure 3 from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Ikeda Yuji , Park Jae-Hyun , Miyamoto Takashi , Takamatsu Naofumi , Kato Taigo , Iwasa Akiko , Okabe Shuhei , Imai Yuichi , Fujiwara Keiichi , Nakamura Yusuke , Hasegawa Kosei
Published: April 2023

MTT assay of OTS514 in 11 ovarian cancer cell lines.
Supplementary figure 1 from T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer
Authors: Ikeda Yuji , Park Jae-Hyun , Miyamoto Takashi , Takamatsu Naofumi , Kato Taigo , Iwasa Akiko , Okabe Shuhei , Imai Yuichi , Fujiwara Keiichi , Nakamura Yusuke , Hasegawa Kosei
Published: April 2023

mRNA expression status of TOPK in Oncomine database.
Supplementary Table 1 from Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer
Authors: Rachner Tilman D. , Kasimir-Bauer Sabine , Göbel Andy , Erdmann Kati , Hoffmann Oliver , Browne Andrew , Wimberger Pauline , Rauner Martina , Hofbauer Lorenz C. , Kimmig Rainer , Bittner Ann-Kathrin
Published: April 2023

Detailed treatment of cohort
Video for Biochemical, molecular, and clinical characterization of SDHA VUS from Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance
Authors: Bannon Amber E. , Kent Jason , Forquer Isaac , Town Ajia , Klug Lillian R. , McCann Kelly , Beadling Carol , Harismendy Oliver , Sicklick Jason K. , Corless Christopher , Shinde Ujwal , Heinrich Michael C.
Published: April 2023

Video for Biochemical, molecular, and clinical characterization of SDHA VUS from Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance
Supplementary Table 1 from Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations
Authors: Tetzlaff Michael T. , Curry Jonathan L. , Ning Jing , Sagiv Oded , Kandl Thomas L. , Peng Bo , Bell Diana , Routbort Mark , Hudgens Courtney W. , Ivan Doina , Kim Tae-Boom , Chen Ken , Eterovic Agda Karina , Shaw Kenna , Prieto Victor G. , Yemelyanova Anna , Esmaeli Bita
Published: April 2023

Supplementary Table 1. Summary of mutations identified in the entire cohort of primary, locally recurrent and metastatic tumors.
Supplementary Data from Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
Authors: Day Terry A. , Shirai Keisuke , O'Brien Paul E. , Matheus Maria Gisele , Godwin Kristina , Sood Amit J. , Kompelli Anvesh , Vick Julie A. , Martin Daniel , Vitale-Cross Lynn , Callejas-Varela Juan Luis , Wang Zhiyong , Wu Xingyu , Harismendy Olivier , Molinolo Alfredo A. , Lippman Scott M. , Van Waes Carter , Szabo Eva , Gutkind J. Silvio
Published: April 2023

Supplemental Table 1. Statistics of whole exome sequencing. Supplemental Table 2. List of filtered variants per patient. Supplemental Table 3. Summary of variants per patient.
Supplementary Table 5 from AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Authors: Yi Xue , Sarkar Aloke , Kismali Gorkem , Aslan Burcu , Ayres Mary , Iles LaKesla R. , Keating Michael J. , Wierda William G. , Long James P. , Bertilaccio Maria Teresa Sabrina , Gandhi Varsha
Published: April 2023

Supplementary Table 5
Supplementary Table 2 from AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia
Authors: Yi Xue , Sarkar Aloke , Kismali Gorkem , Aslan Burcu , Ayres Mary , Iles LaKesla R. , Keating Michael J. , Wierda William G. , Long James P. , Bertilaccio Maria Teresa Sabrina , Gandhi Varsha
Published: April 2023

Supplementary Table 2
Supplementary Table 2 from Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Authors: Polk Avery , Lu Ye , Wang Tianjiao , Seymour Erlene , Bailey Nathanael G. , Singer Jack W. , Boonstra Philip S. , Lim Megan S. , Malek Sami , Wilcox Ryan A.
Published: April 2023

Pacritinib kinase profile
Supplementary materials and methods from C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes
Authors: Wang Xiaohong , Liang Qiaoyi , Zhang Lianhai , Gou Hongyan , Li Ziyu , Chen Huarong , Dong Yujuan , Ji Jiafu , Yu Jun
Published: April 2023

Supplementary materials and methods
Figure S4 from C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes
Authors: Wang Xiaohong , Liang Qiaoyi , Zhang Lianhai , Gou Hongyan , Li Ziyu , Chen Huarong , Dong Yujuan , Ji Jiafu , Yu Jun
Published: April 2023

DUSP5P1 promotes GC cell proliferation in vitro.
Supplementary Figure 2 from Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia
Authors: Polk Avery , Lu Ye , Wang Tianjiao , Seymour Erlene , Bailey Nathanael G. , Singer Jack W. , Boonstra Philip S. , Lim Megan S. , Malek Sami , Wilcox Ryan A.
Published: April 2023

Viable CLL cells may be identified by forward and side scatter characteristics.
Figure S2 from C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes
Authors: Wang Xiaohong , Liang Qiaoyi , Zhang Lianhai , Gou Hongyan , Li Ziyu , Chen Huarong , Dong Yujuan , Ji Jiafu , Yu Jun
Published: April 2023

Protein expression of EMT markers was modulated by C8orf76.
Supplementary Table S2 from Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study
Authors: Peeters Marc , Price Timothy , Boedigheimer Michael , Kim Tae Won , Ruff Paul , Gibbs Peter , Thomas Anne , Demonty Gaston , Hool Kristina , Ang Agnes
Published: April 2023

Patient Ascertainment for Extended RAS Analysis